BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20850731)

  • 1. Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study.
    Liu J; Allgood A; Derogatis LR; Swanson S; O'Mahony M; Nedoss B; Soper H; Zbella E; Prokofieva SV; Zipfel L; Guo CY
    Fertil Steril; 2011 Jan; 95(1):366-8. PubMed ID: 20850731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women.
    Simon J; Klaiber E; Wiita B; Bowen A; Yang HM
    Menopause; 1999; 6(2):138-46. PubMed ID: 10374221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined esterified estrogens and methyltestosterone versus esterified estrogens alone in the treatment of loss of sexual interest in surgically menopausal women.
    Warnock JK; Swanson SG; Borel RW; Zipfel LM; Brennan JJ;
    Menopause; 2005; 12(4):374-84. PubMed ID: 16037752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause.
    Watts NB; Notelovitz M; Timmons MC; Addison WA; Wiita B; Downey LJ
    Obstet Gynecol; 1995 Apr; 85(4):529-37. PubMed ID: 7898828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens.
    Utian WH; Lederman SA; Williams BM; Vega RY; Koltun WD; Leonard TW
    Obstet Gynecol; 2004 Feb; 103(2):245-53. PubMed ID: 14754691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose estrogen therapy for menopausal women: a review of efficacy and safety.
    Crandall C
    J Womens Health (Larchmt); 2003 Oct; 12(8):723-47. PubMed ID: 14588124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study.
    Stevenson JC; Durand G; Kahler E; Pertyński T
    Maturitas; 2010 Nov; 67(3):227-32. PubMed ID: 20688442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles.
    Barrett-Connor E; Young R; Notelovitz M; Sullivan J; Wiita B; Yang HM; Nolan J
    J Reprod Med; 1999 Dec; 44(12):1012-20. PubMed ID: 10649811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women.
    Hickok LR; Toomey C; Speroff L
    Obstet Gynecol; 1993 Dec; 82(6):919-24. PubMed ID: 8233265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esterified estrogens combined with methyltestosterone raise intraocular pressure in postmenopausal women.
    Khurana RN; LaBree LD; Scott G; Smith RE; Yiu SC
    Am J Ophthalmol; 2006 Sep; 142(3):494-5. PubMed ID: 16935599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose transdermal estrogens.
    Med Lett Drugs Ther; 2007 Aug; 49(1268):71-2. PubMed ID: 17712292
    [No Abstract]   [Full Text] [Related]  

  • 12. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses.
    Sarrel P; Dobay B; Wiita B
    J Reprod Med; 1998 Oct; 43(10):847-56. PubMed ID: 9800666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perimenopausal women in estrogen vasomotor trials: contribution to placebo effect and efficacy outcome.
    Simon JA; Stevens RE; Ayres SA; Phelps KV
    Climacteric; 2001 Mar; 4(1):19-27. PubMed ID: 11379374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy.
    Tuomikoski P; Haapalahti P; Sarna S; Ylikorkala O; Mikkola TS
    Ann Med; 2010 Jul; 42(5):334-43. PubMed ID: 20429800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
    Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
    Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1mg estradiol valerate/2mg dienogest on hot flushes in postmenopausal women.
    Endrikat J; Graeser T; Mellinger U; Ertan K; Holz C
    Maturitas; 2007 Oct; 58(2):201-7. PubMed ID: 17889463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire.
    Lobo RA; Rosen RC; Yang HM; Block B; Van Der Hoop RG
    Fertil Steril; 2003 Jun; 79(6):1341-52. PubMed ID: 12798881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
    Speroff L; Gass M; Constantine G; Olivier S;
    Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety.
    Archer DF; Dupont CM; Constantine GD; Pickar JH; Olivier S;
    Am J Obstet Gynecol; 2009 Mar; 200(3):238.e1-238.e10. PubMed ID: 19167693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial.
    Frei-Kleiner S; Schaffner W; Rahlfs VW; Bodmer Ch; Birkhäuser M
    Maturitas; 2005 Aug; 51(4):397-404. PubMed ID: 16039414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.